Dear Commissioner Borg,
We welcome the European Commission’s 12-point action plan of 15 November 2011 for controlling antimicrobial resistance. While the proposals cover the main areas in general terms, we are concerned that detailed proposals to address this serious issue have yet to be published. We feel it is essential that an EU-wide strategy is developed which will be effective in reducing the overuse of antibiotics in agriculture to the minimum required for maintaining animal welfare. We hope that the Commission will include measures with this aim in mind in the forthcoming revision of EU legislation on veterinary medicines and medicated feedingstuffs.
The European Union provided global leadership by phasing out the use of antibiotic growth promoters between 1997 and 2006. A key goal of this action was to reduce the levels of resistant enterococci in farm animals and in humans, and data collected since then shows that this has been achieved . This demonstrates that the rise of antibiotic resistance can be slowed, or even reversed, if firm regulatory action is taken in time.
However, it is widely recognised that many livestock producers responded to the growth-promoter ban by increasing their use of other antibiotics under veterinary prescription. Some of these antibiotics, frequently used for ‘prophylaxis’ (disease prevention) at sub-therapeutic levels in healthy animals, are even more important in human medicine than some of the banned growth promoters, particularly for the treatment of Salmonella, Campylobacter and E. coli infections, which are often of farm-animal origin.
As the Commission has previously made clear, the inappropriate use of antibiotics in human medicine also remains a serious problem, which requires further action. However, this must not detract from the clear evidence that the excessive administration of antibiotics to farm animals is increasingly contributing to treatment problems in human medicine, while also having the potential to create a serious treatment crisis in livestock production as well.
The European Food Safety Authority has said that ‘Resistant Salmonella and Campylobacter involved in human disease are mostly spread through foods’ . Regarding E. coli, EFSA has said that ‘Some categories of food may often be contaminated with E. coli, including resistant isolates, and these bacteria reside long enough in the intestines of humans to transfer resistance genes to the residential flora. It is therefore highly probable that food is a vehicle for spread of resistance genes between different ecosystems’ .
The WHO similarly states that ‘Resistance in the foodborne zoonotic bacteria Salmonella and Campylobacter is clearly linked to antibiotic use in food animals, and foodborne diseases caused by such resistant bacteria are well documented in people’ and ‘Resistant E. coli can spread from animals to people through the food chain’ .
Furthermore, in many European countries over the past decade there have been large increases in use of the critically important antibiotics, the modern cephalosporins and the fluoroquinolones, which have broad-spectrum activity. This has led to the emergence of livestock-associated strains of MRSA, like ST398, and of extended-spectrum beta-lactamase (ESBL) E. coli in farm animals. Our analysis, detailed in the enclosed briefing paper, concludes that it is now beyond reasonable doubt that the current use of antimicrobials in farm animals is contributing to levels of antimicrobial resistance in life-threatening infections in the human population, making prompt and successful treatment more problematic.
As a result of the strength of the evidence, the European Medicines Agency (EMA), EFSA and the WHO have all said that there is a need to reduce the levels of resistance being transmitted from livestock to humans, and highlighted reduced antibiotic use as probably the most effective method available. We warmly welcome recent actions that the EU has taken for restricting some uses of critically important antibiotics, particularly the modern cephalosporins , but believe that much more remains to be done. In particular, we ask you to include the following as part of an overall strategy for the reduction in the use of antibiotics in farm animals:
1. A legally binding timetable to phase out routine prophylactic use of antibiotics.
We welcome the EMA’s 2011 clarification that, for products authorised through the centralised procedure, prophylactic use is not permitted unless the presence of the disease has been established . We are calling on you to ensure that this is extended to all antibiotic products, including those licensed through the decentralised and mutual-recognition procedures, and given legal force by inclusion in revised veterinary-medicines and medicated-feed legislation. At present, it is clear that many within the industry continue to use antibiotics for routine prophylaxis, in the absence of disease, and to believe that this is acceptable practice .
2. The ban on the use of modern cephalosporins in poultry must be fully implemented, and a ban should also be introduced on their use in pigs and for dry-cow therapy in cattle.
We welcome the Commission’s Implementing Decision of 13 January 2012 that Member States must add a statement to the Summary of Product Characteristics (SPCs) for modern cephalosporins, saying that the product must not be used in poultry. It is important that the Commission ensures that this is acted upon and then monitored throughout the EU. Danish and Dutch pig producers have already introduced voluntary bans on the use of modern cephalosporins. Very recently published research found that the occurrence of ESBL E. coli in Danish pigs at slaughter fell from 11.8% in 2010 to 3.6% in 2011 after the voluntary ban was introduced in July 2010. The decline in resistance for pigs tested on farms was even larger, from 11% in 2010 to 0% in 2011 . Dutch dairy farmers have also introduced a voluntary ban on the use of modern cephalosporins for dry-cow therapy. According to the Dutch Chief Veterinary Officer, these voluntary bans contributed to a 92% reduction in the Dutch farm use of these antibiotics between 2009 and 2012.
3. Modern cephalosporins should no longer be permitted to be used off-label.
The risk of ESBL resistance and MRSA transferring from farm animals to humans is too great to permit use of these antibiotics in animals which is not fully regulated.
4. A ban on the use of fluoroquinolones in poultry.
Fluoroquinolones are critically important antibiotics in human medicine because of their importance for treating infections such as Campylobacter, Salmonella and E. coli. Poultry are recognised as a key source of these infections in humans, and in the case of Campylobacter, by far the most important source. The United States banned the use of these antibiotics in poultry for this reason.
5. New legislation aimed at improving animal health and welfare and ensuring that farm animals are kept in less-intensive conditions with, wherever possible, access to the outdoors.
It is essential that a farm-animal health and welfare strategy should be recognised as a key tool in helping to address the rise of antibiotic resistance. Improving animal health through increased animal welfare, better system design and the selection of breeds that are less susceptible to disease can dramatically reduce the need for antibiotics.
We strongly support the steps the Commission and other EU institutions have already taken in relation to antibiotic resistance of farm-animal origin, and hope that these are just the first steps in the development of a much more responsible and sustainable European antibiotic policy.
Dill Peeling, Director of Public Affairs, Compassion in World Farming
Peter Melchett, Policy Director, Soil Association
Jeanette Longfield, Coordinator, Sustain: The alliance for better food and farming
Professor Lindsey Davies, President, Faculty of Public Health (FPH)
Professor Chris Butler, Director, Institute of Primary Care & Public Health, Cardiff University School of Medicine
Steve Nash, Co Founder Member, HUSH, The UK E.coli Support Group
Jeremy Wates, Secretary General, European Environment Bureau
Adrian Bebb, Food, Agriculture and Biodiversity Programme, Friends of the Earth Europe
Gabriella Zanzanaini, Director of European Affairs, Food and Water Europe
Rodrigo Gouveia, Secretary General, Euro Coop
Gabriela Papadopova, President, Intimate With Nature Society (IWNS)
Sir Julian Rose, President, International Coalition to Protect the Polish Countryside
Patrick Holden CBE, Founder, Sustainable Food Trust
Samuel Féret, Coordinator, ARC2020
Tracy Worcester, Director, Farms not Factories
Mahi Klosterhalfen, Executive Vice President, Albert Schweitzer Stiftung
Libby Anderson, One Kind
Mariana Sanz de Galdeano Albizúa, President, AND
Ann de Greef, Director, GAIA (Global Action in the Interest of Animals)
 WHO, 2011. Tackling antibiotic resistance from a food safety perspective in Europe, http://www.euro.who.int/__data/assets/pdf_file/0005/136454/e94889.pdf
 European Food Safety Authority, 2008. Foodborne antimicrobial resistance as a biological hazard, Scientific Opinion of the Panel on Biological Hazards, Adopted on 9 July 2008, http://www.efsa.europa.eu/de/scdocs/doc/765.pdf
 Commission Implementing Decision concerning, in the framework of Article 35 of Directive 2001/82/EC of the European Parliament and of the Council; the marketing authorisations for veterinary medicinal products which contain the active substances “Cefquinome and Ceftiofur”
 European Medicines Agency, 2011. Question and answer on the CVMP guideline on the SPC for antimicrobial products (EMEA/CVMP/SAGAM/383441/2005), http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/07/WC500109155.pdf
 Responsible Use of Medicines in Agriculture, 2012. RUMA comment on the Early Day Motion in the House of Commons on the use of antibiotics in intensive farming, http://www.ruma.org.uk/news/20121105.htm This press release by the alliance representing the pharmaceutical and farming industries argues against a Parliamentary motion calling for a ban on ‘routine prophylactic use’. RUMA also explicitly says that it ‘does not consider the delay of treatment until the development of clinical signs of disease is always appropriate’, apparently in breach of the EMA’s 2011 clarification.
 Agersø Y. and Aarestrup F.M., 2013. Voluntary ban on cephalosporin use in Danish pig production has effectively reduced extended-spectrum cephalosporinase-producing Escherichia coli in slaughter pigs, Journal of Antimicrobial Chemotherapy, 68: 569-72
Photograph by Nicholas Vinacco
Sign up to our Newsletter
Stay up to date with the latest SFT views and news